New study led by U. Pitt researcher shows mirtazapine cuts risk of depression relapse by more than 50 percent

December 14, 1999

Mirtazapine Also Shown to Relieve Depression More Rapidly Than Some Commonly Prescribed SSRIs

PITTSBURGH, Dec. 15 -- A study led by a University of Pittsburgh researcher being presented at the annual meeting of the American College of Neuropsychopharmacology (ACNP) today in Acapulco found that twice as many placebo-treated patients experienced a relapse of their depression versus those who continued treatment with the antidepressant Remeron® (mirtazapine). Additional data presented at the meeting demonstrated that mirtazapine, a dual-action antidepressant, relieves depression more quickly than some commonly prescribed selective serotonin reuptake inhibitor (SSRI) antidepressants.

Depression and related mood disorders cost U.S. society an estimated $16 billion annually1. Depressive disorders account for 7.4 million hospital days and 13 million physician visits a year, and affect 4.8 million people 18 or older in any six-month period, according to the Agency for Health Care Policy and Research. Each year, 16,000 suicides or 7 deaths per 100,000 occur due to depression.2

In a multi-center study led by Michael Thase, M.D., Professor, Department of Psychiatry, University of Pittsburgh School of Medicine, the relapse rate for patients on mirtazapine was less than half that of patients on placebo in the 40-week double-blind study. The initial phase of the study included patients who had chronic or recurrent major depressive episodes. Those patients who received treatment with mirtazapine and recovered from their depression advanced to the double-blind phase of the trial, in which 79 patients continued therapy with mirtazapine and 81 were switched to placebo. Twice as many mirtazapine-treated patients remained in remission during the double-blind phase.

Dr. Thase said, "It is not uncommon for patients who have recovered from a depressive episode to suffer a relapse. The results of this study tell us we can prevent relapse, and that's very significant for patients."

In addition, data on mirtazapine's speed of efficacy was presented at the ACNP meeting by Andrew Nierenberg, M.D., Associate Professor of Psychiatry, Harvard Medical School and Associate Director of the Depression and Clinical Research Program. The research found that mirtazapine relieved depression faster than some commonly prescribed SSRIs. Dr. Nierenberg and his colleagues analyzed three double-blind, controlled studies of mirtazapine compared with Prozac® (fluoxetine), Paxil® (paroxetine), and Celexa™ (citalopram) in 642 depressed patients. Within the first week, the patients taking mirtazapine showed a greater improvement in their depressive symptoms more quickly than patients on fluoxetine and paroxetine. In this particular study, the difference between mirtazapine and citalopram was not statistically significant.

"While SSRIs are highly safe and effective, they exhibit a delay in onset of therapeutic action," said Dr. Nierenberg. "Mirtazapine's dual action on both norepinephrine and serotonin in the brain may contribute to its ability to relieve depression more quickly."
Remeron(R) (mirtazapine) is marketed in the United States by Organon Inc. of West Orange, NJ, a division of Akzo Nobel.

The University of Pittsburgh School of Medicine is consistently ranked among the nation's leading medical schools. Among the many areas for which its faculty and programs are internationally recognized are psychiatry, oncology, genetics, transplantation and public health.

1. The AHCPR guidelines for the treatment of depression 5b. Depression in Primary Care - Treatment (Clinical Guide)
Executive Summary.
2. Stoudemire A, Frank R, Hedemark N, Kamlet M, Blazer D. The economic burden of depression. Gen Hosp Psychiatry 1986; 8:387-94.


Related Depression Articles from Brightsurf:

Children with social anxiety, maternal history of depression more likely to develop depression
Although researchers have known for decades that depression runs in families, new research from Binghamton University, State University of New York, suggests that children suffering from social anxiety may be at particular risk for depression in the future.

Depression and use of marijuana among US adults
This study examined the association of depression with cannabis use among US adults and the trends for this association from 2005 to 2016.

Maternal depression increases odds of depression in offspring, study shows
Depression in mothers during and after pregnancy increased the odds of depression in offspring during adolescence and adulthood by 70%.

Targeting depression: Researchers ID symptom-specific targets for treatment of depression
For the first time, physician-scientists at Beth Israel Deaconess Medical Center have identified two clusters of depressive symptoms that responded to two distinct neuroanatomical treatment targets in patients who underwent transcranial magnetic brain stimulation (TMS) for treatment of depression.

A biological mechanism for depression
Researchers report that in depressed individuals there are increased amounts of an unmodified structural protein, called tubulin, in lipid rafts compared with non-depressed individuals.

Depression in adults who are overweight or obese
In an analysis of primary care records of 519,513 UK adults who were overweight or obese between 2000-2016 and followed up until 2019, the incidence of new cases of depression was 92 per 10,000 people per year.

Why stress doesn't always cause depression
Rats susceptible to anhedonia, a core symptom of depression, possess more serotonin neurons after being exposed to chronic stress, but the effect can be reversed through amygdala activation, according to new research in JNeurosci.

Which comes first: Smartphone dependency or depression?
New research suggests a person's reliance on his or her smartphone predicts greater loneliness and depressive symptoms, as opposed to the other way around.

Depression breakthrough
Major depressive disorder -- referred to colloquially as the 'black dog' -- has been identified as a genetic cause for 20 distinct diseases, providing vital information to help detect and manage high rates of physical illnesses in people diagnosed with depression.

CPAP provides relief from depression
Researchers have found that continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA) can improve depression symptoms in patients suffering from cardiovascular diseases.

Read More: Depression News and Depression Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to